OBJECTIVES: We evaluated the cost-effectiveness of fee-based and free testing strategies at an HIV voluntary counseling and testing (VCT) program integrated into a community-based AIDS service organization in Moshi, Tanzania. METHODS: We waived the usual fee schedule during a 2-week free, advertised VCT campaign; analyzed the number of clients testing per day during prefree, free, and postfree testing periods; and estimated the cost-effectiveness of limited and sustained free testing strategies. RESULTS: The number of clients testing per day increased from 4.1 during the prefree testing interval to 15.0 during the free testing campaign (P<.0001) and remained significantly increased at 7.1 (P<.0001) after resumption of the standard fees. HIV seroprevalence (16.7%) and risk behaviors were unchanged over these intervals. Modeled over 1 year, the costs per infection averted with the standard fee schedule, with a 2-week free VCT campaign, and with sustained free VCT year-round were $170, $105, and $92, respectively, and the costs per disability-adjusted life year gained were $8.72, $5.40, and $4.72, respectively. CONCLUSIONS: The provision of free VCT enhances both the number of clients testing per day and its cost-effectiveness in resource-limited settings.
OBJECTIVES: We evaluated the cost-effectiveness of fee-based and free testing strategies at an HIV voluntary counseling and testing (VCT) program integrated into a community-based AIDS service organization in Moshi, Tanzania. METHODS: We waived the usual fee schedule during a 2-week free, advertised VCT campaign; analyzed the number of clients testing per day during prefree, free, and postfree testing periods; and estimated the cost-effectiveness of limited and sustained free testing strategies. RESULTS: The number of clients testing per day increased from 4.1 during the prefree testing interval to 15.0 during the free testing campaign (P<.0001) and remained significantly increased at 7.1 (P<.0001) after resumption of the standard fees. HIV seroprevalence (16.7%) and risk behaviors were unchanged over these intervals. Modeled over 1 year, the costs per infection averted with the standard fee schedule, with a 2-week free VCT campaign, and with sustained free VCT year-round were $170, $105, and $92, respectively, and the costs per disability-adjusted life year gained were $8.72, $5.40, and $4.72, respectively. CONCLUSIONS: The provision of free VCT enhances both the number of clients testing per day and its cost-effectiveness in resource-limited settings.
Authors: Prabhat Jha; Anne Mills; Kara Hanson; Lilani Kumaranayake; Lesong Conteh; Christoph Kurowski; Son Nam Nguyen; Valeria Oliveira Cruz; Kent Ranson; Lara M E Vaz; Shengchao Yu; Oliver Morton; Jeffrey D Sachs Journal: Science Date: 2002-03-15 Impact factor: 47.728
Authors: Steven Forsythe; Gilly Arthur; Gilbert Ngatia; Roselyn Mutemi; Joseph Odhiambo; Charles Gilks Journal: Health Policy Plan Date: 2002-06 Impact factor: 3.344
Authors: H Y Chu; J A Crump; J Ostermann; R B Oenga; D K Itemba; A Mgonja; S Mtweve; J A Bartlett; J F Shao; N M Thielman Journal: Int J STD AIDS Date: 2005-10 Impact factor: 1.359
Authors: Peter Godfrey-Faussett; Dermot Maher; Ya Diul Mukadi; Paul Nunn; Joseph Perriëns; Mario Raviglione Journal: Bull World Health Organ Date: 2003-01-23 Impact factor: 9.408
Authors: Suzanne P Fiorillo; Keren Z Landman; Alison C Tribble; Antipas Mtalo; Dafrosa K Itemba; Jan Ostermann; Nathan M Thielman; John A Crump Journal: AIDS Care Date: 2012-03-01
Authors: Wei Chang; Gabriel Chamie; Daniel Mwai; Tamara D Clark; Harsha Thirumurthy; Edwin D Charlebois; Maya Petersen; Jane Kabami; Emmanuel Ssemmondo; Kevin Kadede; Dalsone Kwarisiima; Norton Sang; Elizabeth A Bukusi; Craig R Cohen; Moses Kamya; Diane V Havlir; James G Kahn Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Laura M Bogart; Glenn J Wagner; William Musoke; Rose Naigino; Sebastian Linnemayr; Emily Maistrellis; David J Klein; Riana B Jumamil; Barbara Mukasa; Ingrid V Bassett; Thomas P Giordano; Rhoda K Wanyenze Journal: AIDS Behav Date: 2017-02
Authors: Richard C Waters; Jan Ostermann; Travis D Reeves; Max F Masnick; Nathan M Thielman; John A Bartlett; John A Crump Journal: J Acquir Immune Defic Syndr Date: 2011-04-15 Impact factor: 3.731
Authors: Meghan K Mayhood; Isaac A Afwamba; Christopher O Odhiambo; Epimack Ndanu; Nathan M Thielman; Anne B Morrissey; John F Shao; Brian Wells Pence; John A Crump Journal: J Clin Microbiol Date: 2008-10-15 Impact factor: 5.948